+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarcoma Drugs Market by Drug Class (Antiangiogenic Therapy, Chemotherapy, Hormonal Therapy), Indication (Bone Sarcoma, Gastrointestinal Stromal Tumors, Kaposi Sarcoma), Route Of Administration, End User, Treatment Modality - Global Forecast 2025-2030- Product Image
Sarcoma Drugs Market by Drug Class (Antiangiogenic Therapy, Chemotherapy, Hormonal Therapy), Indication (Bone Sarcoma, Gastrointestinal Stromal Tumors, Kaposi Sarcoma), Route Of Administration, End User, Treatment Modality - Global Forecast 2025-2030- Product Image
Sale

Sarcoma Drugs Market by Drug Class (Antiangiogenic Therapy, Chemotherapy, Hormonal Therapy), Indication (Bone Sarcoma, Gastrointestinal Stromal Tumors, Kaposi Sarcoma), Route Of Administration, End User, Treatment Modality - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083365
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global sarcoma drugs market is experiencing transformative growth fueled by advancements in molecular technology, precision medicine, and strategic industry partnerships. Senior decision-makers navigating this sector will find a dynamic landscape evolving in both scope and competitive complexity, with opportunities and challenges across clinical, regulatory, and economic fronts.

Market Snapshot: Sarcoma Drugs and Growth Trajectory

The sarcoma drugs market is projected to grow from USD 1.66 billion in 2024 to USD 1.80 billion in 2025, maintaining a compound annual growth rate (CAGR) of 8.14%, and reaching USD 2.66 billion by 2030. This expansion reflects increased demand for precision therapies, rapid innovation in drug development platforms, and shifting treatment paradigms that favor patient-centric approaches.

Scope & Segmentation

Executive stakeholders will benefit from in-depth market coverage, including detailed breakdowns by class, indication, administration route, end user, treatment modality, and region:

  • Drug Classes: Antiangiogenic therapies (PDGF inhibitors, VEGF inhibitors), chemotherapy (alkylating agents, anthracyclines, antimetabolites, topoisomerase inhibitors), hormonal therapies, immunotherapies (adoptive cell therapies, cancer vaccines, checkpoint inhibitors, cytokine therapy), targeted therapies (CDK4/6 inhibitors, mTOR inhibitors, PARP inhibitors, tyrosine kinase inhibitors).
  • Indications: Bone sarcoma (chondrosarcoma, Ewing sarcoma, osteosarcoma), gastrointestinal stromal tumors, Kaposi sarcoma, soft tissue sarcoma (leiomyosarcoma, liposarcoma, rhabdomyosarcoma, synovial sarcoma).
  • Routes of Administration: Intramuscular, intravenous, oral, subcutaneous administration to address diverse clinical needs and patient compliance.
  • End Users: Ambulatory surgical centers, home care providers, hospitals, and specialty clinics drive access and market differentiation.
  • Treatment Modalities: Combination therapies (such as chemotherapy plus immunotherapy, chemotherapy plus targeted agents, immunotherapy plus targeted agents) and monotherapy approaches meeting evolving standards of care.
  • Regional Coverage: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Technology Use: Integration of high-throughput screening, structure-based drug design, next-generation sequencing, liquid biopsy platforms, and digital supply chain management solutions.
  • Company Developments: Coverage of key players driving progress, such as Novartis AG, Bayer AG, Pfizer Inc., Ipsen S.A., Eisai Co., Ltd., Eli Lilly and Company, Deciphera Pharmaceuticals, LLC, Blueprint Medicines Corporation, Epizyme, Inc., Merck & Co., Inc.

Key Takeaways for Strategic Decision-Makers

  • Innovative therapies and adaptive clinical trial designs are expediting the development pipeline, supporting precision medicine strategies for diverse sarcoma subtypes.
  • Collaborative partnerships between academic, biotech, and pharmaceutical organizations are accelerating clinical translation and facilitating regulatory engagement across multiple regions.
  • Advanced monitoring technologies, such as liquid biopsies and real-time analytics, enable earlier detection of treatment response and resistance, supporting proactive intervention.
  • Regional disparities in access, infrastructure, and regulatory standards influence market entry strategies, pricing, and the speed of product adoption.
  • Supply chain optimization, resilience planning, and digital management are increasingly vital in light of geopolitical shifts and policy interventions affecting global distribution.

Impact of United States Tariffs on the Sarcoma Drugs Market

Tariff adjustments in the United States are creating new pressures on sarcoma drug supply chains. Increased duties on both raw materials and finished formulations are prompting manufacturers to diversify suppliers, optimize logistics, and form localized partnerships. While some organizations are shifting production closer to key markets to reduce financial exposure, added expenses pose downstream challenges in pricing and reimbursement. Stakeholders are leveraging digital supply chain tools and advocating for regulatory exemptions to maintain uninterrupted patient access and protect innovation pipelines.

Methodology & Data Sources

The research methodology blends primary interviews with industry experts, systematic review of scientific literature, analysis of regulatory filings, and triangulation across proprietary databases. Qualitative input is cross-validated by senior analysts to deliver actionable insights and high standards of accuracy.

Why This Report Matters

  • Empowers executive teams with strategic frameworks to allocate R&D resources and align commercial priorities with emerging clinical evidence.
  • Enables organizations to navigate regulatory and tariff-driven market complexities, ensuring sustained access and competitive positioning.

Conclusion

This analysis provides market leaders with the essential context and strategic pathways to thrive in the evolving sarcoma drugs sector. Informed decisions will lead to better patient outcomes and sustained competitive advantage.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in targeted tyrosine kinase inhibitors improving sarcoma survival outcomes
5.2. Rapidly evolving genomic profiling techniques enabling personalized sarcoma drug regimens
5.3. Integration of immunotherapy combinations with chemotherapy in advanced sarcoma treatment pipelines
5.4. Emerging bispecific antibodies targeting dual sarcoma antigens in preclinical and clinical trials
5.5. Regulatory breakthroughs accelerating orphan drug approvals for rare soft tissue sarcoma subtypes
5.6. Market entry of next generation mTOR inhibitors targeting resistant sarcoma cell pathways
5.7. Increasing adoption of real world evidence to inform sarcoma drug pricing and reimbursement strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sarcoma Drugs Market, by Drug Class
8.1. Introduction
8.2. Antiangiogenic Therapy
8.2.1. PDGF Inhibitors
8.2.2. VEGF Inhibitors
8.3. Chemotherapy
8.3.1. Alkylating Agents
8.3.2. Anthracyclines
8.3.3. Antimetabolites
8.3.4. Topoisomerase Inhibitors
8.4. Hormonal Therapy
8.5. Immunotherapy
8.5.1. Adoptive Cell Therapy
8.5.2. Cancer Vaccines
8.5.3. Checkpoint Inhibitors
8.5.4. Cytokine Therapy
8.6. Targeted Therapy
8.6.1. CDK4/6 Inhibitors
8.6.2. MTOR Inhibitors
8.6.3. PARP Inhibitors
8.6.4. Tyrosine Kinase Inhibitors
9. Sarcoma Drugs Market, by Indication
9.1. Introduction
9.2. Bone Sarcoma
9.2.1. Chondrosarcoma
9.2.2. Ewing Sarcoma
9.2.3. Osteosarcoma
9.3. Gastrointestinal Stromal Tumors
9.4. Kaposi Sarcoma
9.5. Soft Tissue Sarcoma
9.5.1. Leiomyosarcoma
9.5.2. Liposarcoma
9.5.3. Rhabdomyosarcoma
9.5.4. Synovial Sarcoma
10. Sarcoma Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Oral
10.5. Subcutaneous
11. Sarcoma Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Home Care
11.4. Hospitals
11.5. Specialty Clinics
12. Sarcoma Drugs Market, by Treatment Modality
12.1. Introduction
12.2. Combination Therapy
12.2.1. Chemotherapy Plus Immunotherapy
12.2.2. Chemotherapy Plus Targeted
12.2.3. Immunotherapy Plus Targeted
12.3. Monotherapy
13. Americas Sarcoma Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Sarcoma Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Sarcoma Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Bayer AG
16.3.3. Pfizer Inc.
16.3.4. Ipsen S.A.
16.3.5. Eisai Co., Ltd.
16.3.6. Eli Lilly and Company
16.3.7. Deciphera Pharmaceuticals, LLC
16.3.8. Blueprint Medicines Corporation
16.3.9. Epizyme, Inc.
16.3.10. Merck & Co., Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SARCOMA DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. SARCOMA DRUGS MARKET: RESEARCHAI
FIGURE 26. SARCOMA DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. SARCOMA DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. SARCOMA DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PDGF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CDK4/6 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EWING SARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RHABDOMYOSARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL SARCOMA DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY PLUS TARGETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY PLUS TARGETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL SARCOMA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 171. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. CANADA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 174. CANADA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 175. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 176. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 177. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 178. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 179. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 180. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 181. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. CANADA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 184. CANADA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 185. CANADA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 186. CANADA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 187. CANADA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. CANADA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. CANADA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. CANADA SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. CANADA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 192. CANADA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 193. CANADA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 194. CANADA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 195. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 198. MEXICO SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 199. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 200. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 201. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 202. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 203. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 204. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 205. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. MEXICO SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 208. MEXICO SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 209. MEXICO SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 210. MEXICO SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 211. MEXICO SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. MEXICO SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. MEXICO SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. MEXICO SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. MEXICO SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 216. MEXICO SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 217. MEXICO SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 218. MEXICO SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 317. GERMANY SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 318. GERMANY SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 319. GERMANY SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 320. GERMANY SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 321. GERMANY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 322. GERMANY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 323. GERMANY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 324. GERMANY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 325. GERMANY SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 326. GERMANY SARCOMA DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 327. GERMANY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 328. GERMANY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 329. GERMANY SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2018-2024 (USD MILLION)
TABLE 330. GERMANY SARCOMA DRUGS MARKET SIZE, BY BONE SARCOMA, 2025-2030 (USD MILLION)
TABLE 331. GERMANY SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2018-2024 (USD MILLION)
TABLE 332. GERMANY SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, 2025-2030 (USD MILLION)
TABLE 333. GERMANY SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 334. GERMANY SARCOMA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 335. GERMANY SARCOMA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. GERMANY SARCOMA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. GERMANY SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
TABLE 338. GERMANY SARCOMA DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2030 (USD MILLION)
TABLE 339. GERMANY SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 340. GERMANY SARCOMA DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 341. FRANCE SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 342. FRANCE SARCOMA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 343. FRANCE SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2018-2024 (USD MILLION)
TABLE 344. FRANCE SARCOMA DRUGS MARKET SIZE, BY ANTIANGIOGENIC THERAPY, 2025-2030 (USD MILLION)
TABLE 345. FRANCE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 346. FRANCE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 347. FRANCE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTH

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Sarcoma Drugs market report include:
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Ipsen S.A.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Deciphera Pharmaceuticals, LLC
  • Blueprint Medicines Corporation
  • Epizyme, Inc.
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.66 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Sarcoma Drugs - Global Strategic Business Report - Product Image

Sarcoma Drugs - Global Strategic Business Report

  • Report
  • 126 Pages
  • Global
From
Sarcoma Drugs Market Report 2025 - Product Image

Sarcoma Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ewing Sarcoma Drug Pipeline Analysis Report 2025 - Product Image

Ewing Sarcoma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Synovial Sarcoma Drug Pipeline Analysis Report 2025 - Product Image

Synovial Sarcoma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Sarcoma Drug Market

Sarcoma is a type of cancer that affects the connective tissues of the body, such as muscle, bone, fat, and blood vessels. Sarcoma drugs are used to treat this type of cancer, and are part of the larger oncology drug market. These drugs are typically used in combination with other treatments, such as surgery, radiation, and chemotherapy. Sarcoma drugs are designed to target the specific type of cancer, and can be used to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of metastasis. The sarcoma drug market is highly competitive, with many companies developing new treatments and therapies. Some of the major players in the market include Pfizer, Merck, Novartis, Bristol-Myers Squibb, and Eli Lilly. Other companies, such as Amgen, AstraZeneca, and Celgene, are also developing treatments for sarcoma. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.